Literature DB >> 15573074

Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma.

Dirk Hellwig1, Thomas P Graeter, Dieter Ukena, Thomas Georg, Carl-Martin Kirsch, Hans-Joachim Schäfers.   

Abstract

OBJECTIVES: Induction therapy is an important treatment option in locally advanced non-small cell lung cancer. F-18-fluorodeoxyglucose positron emission tomography (FDG-PET) has an important role in initial staging. The aim of this study was to assess the value of FDG-PET in restaging after induction therapy and in analyzing tumor viability, nodal status, distant metastases, and prognosis.
METHODS: Forty-seven patients with locally advanced non-small cell lung cancer accepted for resection after induction therapy underwent FDG-PET. Images were interpreted visually for mediastinal nodal status and metastatic spread. The FDG accumulation in the tumor site was measured by using the maximum standardized uptake value.
RESULTS: Unexpected metastases were detected by means of FDG-PET in 9 patients. Surgical intervention was not performed in 8 patients with confirmed metastases. The rate of unexpected findings increased from complete radiologic remission (0%) over partial remission (9%) to no change (67%). The standardized uptake value was higher in tumors with (n = 26) than in those without (n = 11) histologic proof of viability (6.4 +/- 5.3 vs 2.9 +/- 1.6, P = .006). All patients with standardized uptake values of greater than 5.8 had viable tumors. Sensitivity, specificity, and negative predictive value were 81%, 64%, and 58% for tumor viability and 50%, 88%, and 85% for persistent mediastinal disease. Median survival after resection was greater than 56 months for patients with tumor standardized uptake values of less than 4 and 19 months for patients with standardized uptake values of 4 or greater ( P < .001).
CONCLUSION: FDG-PET helps in the selection of patients for resection after induction therapy. It can be used to detect unexpected distant metastases, especially after poor response to induction therapy. Its high negative predictive value in mediastinal restaging allows for omission of repeat mediastinoscopy. Tumor standardized uptake value after induction is a prognostic factor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15573074     DOI: 10.1016/j.jtcvs.2004.07.031

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  19 in total

1.  Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.

Authors:  Dirk Hellwig; Andreas Gröschel; Thomas P Graeter; Anne P Hellwig; Ursula Nestle; Hans-Joachim Schäfers; Gerhard W Sybrecht; Carl-Martin Kirsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-09       Impact factor: 9.236

2.  PET imaging for Treatment Response in Cancer.

Authors:  Janet F Eary
Journal:  PET Clin       Date:  2008-01-01

Review 3.  Targeting gold nanocages to cancer cells for photothermal destruction and drug delivery.

Authors:  Claire M Cobley; Leslie Au; Jingyi Chen; Younan Xia
Journal:  Expert Opin Drug Deliv       Date:  2010-05       Impact factor: 6.648

Review 4.  Monitoring chemotherapy and radiotherapy of solid tumors.

Authors:  Wolfgang A Weber; Hinrich Wieder
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

5.  Gold Nanocages: A Novel Class of Multifunctional Nanomaterials for Theranostic Applications.

Authors:  Jingyi Chen; Miaoxin Yang; Qiang Zhang; Eun Chul Cho; Claire M Cobley; Chulhong Kim; Charles Glaus; Lihong V Wang; Michael J Welch; Younan Xia
Journal:  Adv Funct Mater       Date:  2010-10-04       Impact factor: 18.808

6.  Gold nanocages as photothermal transducers for cancer treatment.

Authors:  Jingyi Chen; Charles Glaus; Richard Laforest; Qiang Zhang; Miaoxian Yang; Michael Gidding; Michael J Welch; Younan Xia
Journal:  Small       Date:  2010-04-09       Impact factor: 13.281

7.  Sarcoidosis development during induction chemotherapy for lung cancer mimicked progressive disease.

Authors:  Hideo Umezu; Masayuki Chida; Takashi Inoue; Osamu Araki; Motohiko Tamura; Masamitsu Tatewaki; Yasutsugu Fukushima; Koichi Honma
Journal:  Gen Thorac Cardiovasc Surg       Date:  2010-08-12

8.  Respiration-averaged CT for attenuation correction in non-small-cell lung cancer.

Authors:  Nai-Ming Cheng; Chih-Teng Yu; Kung-Chu Ho; Yi-Cheng Wu; Yuan-Chang Liu; Chih-Wei Wang; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12-03       Impact factor: 9.236

9.  Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.

Authors:  Colleen M Costelloe; Hubert H Chuang; John E Madewell; Naoto T Ueno
Journal:  J Cancer       Date:  2010-06-28       Impact factor: 4.207

Review 10.  From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Authors:  Richard L Wahl; Heather Jacene; Yvette Kasamon; Martin A Lodge
Journal:  J Nucl Med       Date:  2009-05       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.